Trial Profile

Phase I/II Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 19 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carfilzomib (Primary) ; Melphalan; Prednisone
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Acronyms CARMYSAP

Most Recent Events

06 Dec 2016 Results (n=32) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
17 Jan 2015 Status changed from recruiting to completed, according to European Clinical Trials Database record.
10 Dec 2013 Interim results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com